Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKayıkçı, Ömür
dc.contributor.authorMehtap, Ö.
dc.contributor.authorSarı, İ.
dc.contributor.authorDemirkan, F.
dc.contributor.authorBeyan, C.
dc.contributor.authorÇetin, G.
dc.contributor.authorTekgündüz, E.
dc.contributor.authorAkpınar, Seval
dc.date.accessioned2023-04-20T08:04:17Z
dc.date.available2023-04-20T08:04:17Z
dc.date.issued2022
dc.identifier.issn1300-7777
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2022.2022.0052
dc.identifier.urihttps://hdl.handle.net/20.500.11776/11069
dc.description.abstractObjective: Peripheral T-cell lymphomas (PTCLs) are an uncommon and quite heterogeneous group of disorders, representing only 10%-15% of all non-Hodgkin lymphomas. Although both molecular and clinical studies have increased in recent years, we still have little knowledge regarding real-life practice with PTCLs. In this study, we aimed to investigate the clinical characteristics and treatment outcomes of a large population-based cohort of patients presenting with systemic non-cutaneous PTCL. Materials and Methods: We conducted a multicenter retrospective analysis of 190 patients consecutively diagnosed and treated with non-cutaneous PTCLs between 2008 and 2016. Results: Considering all first-line treatment combinations, the overall response rate was 65.9% with 49.4% complete remission (n=81) and 16.5% partial response (n=27). The 5-year overall survival and event-free survival rates were significantly different between the transplant and non-transplant groups (p<0.01, and p=0.033, respectively). Conclusion: The retrospective analysis of a large volume of real-life data on the Turkish experience regarding non-cutaneous PTCL patients showed consistent results compared to other unselected PTCL cohorts with some minor differences in terms of survival and transplantation outcomes. The long-term outcome of patients who receive autologous hematopoietic cell transplantation as part of upfront consolidation or salvage therapy is favorable compared to patients who are unable to receive high-dose therapy. © 2022 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.en_US
dc.language.isoengen_US
dc.publisherTurkish Society of Hematologyen_US
dc.identifier.doi10.4274/tjh.galenos.2022.2022.0052
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAutologous stem cell transplantationen_US
dc.subjectLymphomasen_US
dc.subjectNon-Hodgkin lymphomaen_US
dc.subjectT-cell lymphomasen_US
dc.subjectanaplastic lymphoma kinaseen_US
dc.subjectfluorodeoxyglucose f 18en_US
dc.subjectantineoplastic agenten_US
dc.subjectabdomenen_US
dc.subjectadulten_US
dc.subjectanaplastic large cell lymphomaen_US
dc.subjectArticleen_US
dc.subjectautologous hematopoietic stem cell transplantationen_US
dc.subjectautologous stem cell transplantationen_US
dc.subjectbiopsyen_US
dc.subjectbone marrow biopsyen_US
dc.subjectcancer patienten_US
dc.subjectcancer prognosisen_US
dc.subjectcancer survivalen_US
dc.subjectcomputer assisted tomographyen_US
dc.subjectfemaleen_US
dc.subjecthematopoietic cellen_US
dc.subjecthumanen_US
dc.subjecthuman tissueen_US
dc.subjectInternational Prognostic Indexen_US
dc.subjectliver function testen_US
dc.subjectlymph nodeen_US
dc.subjectmaleen_US
dc.subjectmulticenter studyen_US
dc.subjectnecken_US
dc.subjectNon Cutaneous Peripheral T Cell Lymphomaen_US
dc.subjectnonhodgkin lymphomaen_US
dc.subjectoverall response rateen_US
dc.subjectoverall survivalen_US
dc.subjectpelvisen_US
dc.subjectperipheral T cell lymphomaen_US
dc.subjectphysical examinationen_US
dc.subjectpositron emission tomographyen_US
dc.subjectprogression free survivalen_US
dc.subjectremissionen_US
dc.subjectretrospective studyen_US
dc.subjectrisk factoren_US
dc.subjectsalvage therapyen_US
dc.subjectthoraxen_US
dc.subjecttransplantationen_US
dc.subjecttreatment outcomeen_US
dc.subjectautotransplantationen_US
dc.subjectclinical trialen_US
dc.subjecthematologyen_US
dc.subjecthematopoietic stem cell transplantationen_US
dc.subjectpathologyen_US
dc.subjectperipheral T cell lymphomaen_US
dc.subjectproceduresen_US
dc.subjecttreatment outcomeen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectHematologyen_US
dc.subjectHematopoietic Stem Cell Transplantationen_US
dc.subjectHumansen_US
dc.subjectLymphoma, T-Cell, Peripheralen_US
dc.subjectRetrospective Studiesen_US
dc.subjectTransplantation, Autologousen_US
dc.subjectTreatment Outcomeen_US
dc.titleReal-Life Experience Regarding Clinical Characteristics and Treatment Outcome in Non-Cutaneous Peripheral T-Cell Lymphomas: A Multicenter Study of the Turkish Hematology Research and Education Group (ThREG)en_US
dc.title.alternativeNon-kutanöz Periferik T-hücreli Lenfomalarda Klinik Özellikler ve Tedavi Sonuçlarına ilişkin Gerçek Yaşam Deneyimi:Türk Hematoloji Araştırma ve Eğitim Grubunun Çok Merkezli Çalışmasıen_US
dc.typearticleen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.identifier.volume39en_US
dc.identifier.issue3en_US
dc.identifier.startpage170en_US
dc.identifier.endpage177en_US
dc.institutionauthorAkpınar, Seval
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid37002887000
dc.authorscopusid16203384500
dc.authorscopusid57867202100
dc.authorscopusid7005094713
dc.authorscopusid7003953248
dc.authorscopusid56348383300
dc.authorscopusid6603070081
dc.identifier.scopus2-s2.0-85137000431en_US
dc.identifier.pmid35678126en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster